NIKKEI 225
39,103.22 +486.12 (+1.26%) HANG SENG
18,868.71 -326.89 (-1.70%) CRUDE OIL
76.94 +0.07 (+0.09%) GOLD FUTURES
2,331.40 -5.80 (-0.25%) DOW
39,065.26 -605.78 (-1.53%) Bitcoin GBP
53,323.08 -1,275.21 (-2.34%)
ARCT Sep 2024 50.000 call
| Previous close | 0.4000 |
| Open | 0.5000 |
| Bid | 0.0000 |
| Ask | 1.7000 |
| Strike | 50.00 |
| Expiry date | 2024-09-20 |
| Day's range | 0.3500 - 0.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 28 |
GlobeNewswireAchilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
Combines Achilles’ best-in-class AI-driven, tumor-targeting technology with Arcturus’ world-leading self-amplifying mRNA platform Combined technologies have the potential to generate potent and durable T cell responses in pre-clinical IND-enabling studies LONDON, May 22, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced a research collaboration with
PR NewswireNature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announce Nature Communications has published results from an integrated phase 1/2/3a/3b study evaluating the safety, immunogenicity, and efficacy of ARCT, 154, a novel self-amplifying (sa-mRNA) COVID-19 vaccine and the world's first approved sa-mRNA COVID-19 vaccine.
Business WireArcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
SAN DIEGO, May 15, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor and scientific conferences:
